Amplion

Name: Amplion
Brand: Amplion

Identify life science opportunities that match your specific capabilities in a flash. Opportunities won. Deals done.

Est 2013|Valuation $16.5M|Raised $8.7M|4 Ref Customers

LinkedIn 7K|Website|FTEs 51|HQ Arlington, Virginia, US

MarketsList Building & Enrichment Account Research

01Competitive Landscape

| Aspect | Amplion | ZoomInfo (GTM Workspace / SalesOS) | Zymewire | |--------|---------|-------------------------------------|----------| | Starting Price | Not public (demo/quote-led) | Not public list price (typically contract) | Not public list price (typically contract) | | Most suitable for | Life sciences commercial teams needing scientific-context signals and targeted account/program discovery | Broad B2B prospecting and contact data across industries; high-volume outbound | Life sciences sales intelligence with industry-specific targeting (biopharma/biotech ecosystem) | | Key Strength | Domain-specific evidence sources (publications, trials, grants) plus ICP matching and alerts | Large cross-industry contact database and mature integration ecosystem | Life-science-specific dataset focus and ecosystem mapping | | Key Weakness | Sparse third-party reviews; limited public security/compliance documentation; pricing opacity | Can be expensive; data quality varies by segment; privacy/data-broker concerns for the category | Enterprise pricing profile; fit depends on specific segment and use case |

Narrative analysis

- Areas where Amplion may be relatively strong - Scientific and program context: organizations targeting labs, translational research, and clinical program signals may find Amplion’s evidence-based approach more relevant than generic firmographic databases. - Alignment to business development and partnership motions: monitoring grants, publications, and trial activity can provide context for timing outreach. - Areas where competitors often have advantages - ZoomInfo/Apollo - Typically stronger for broad outbound at scale and contact enrichment across multiple industries, with an extensive integration ecosystem and operational maturity. - Zymewire - Frequently positioned as a direct life-sciences-specific alternative for sales intelligence and may have broader awareness in some biopharma sales organizations. - Market adoption signals - A recent acquisition by a strategic buyer indicates intent to fold Amplion capabilities into a broader life-sciences data and insights portfolio.

01Competitive Landscape

Aspect	Amplion	ZoomInfo (GTM Workspace / SalesOS)	Zymewire
Starting Price	Not public (demo/quote-led)	Not public list price (typically contract)	Not public list price (typically contract)
Most suitable for	Life sciences commercial teams needing scientific-context signals and targeted account/program discovery	Broad B2B prospecting and contact data across industries; high-volume outbound	Life sciences sales intelligence with industry-specific targeting (biopharma/biotech ecosystem)
Key Strength	Domain-specific evidence sources (publications, trials, grants) plus ICP matching and alerts	Large cross-industry contact database and mature integration ecosystem	Life-science-specific dataset focus and ecosystem mapping
Key Weakness	Sparse third-party reviews; limited public security/compliance documentation; pricing opacity	Can be expensive; data quality varies by segment; privacy/data-broker concerns for the category	Enterprise pricing profile; fit depends on specific segment and use case

Narrative analysis

Areas where Amplion may be relatively strong
- Scientific and program context: organizations targeting labs, translational research, and clinical program signals may find Amplion’s evidence-based approach more relevant than generic firmographic databases.
- Alignment to business development and partnership motions: monitoring grants, publications, and trial activity can provide context for timing outreach.
Areas where competitors often have advantages
- ZoomInfo/Apollo
  - Typically stronger for broad outbound at scale and contact enrichment across multiple industries, with an extensive integration ecosystem and operational maturity.
- Zymewire
  - Frequently positioned as a direct life-sciences-specific alternative for sales intelligence and may have broader awareness in some biopharma sales organizations.
Market adoption signals
- A recent acquisition by a strategic buyer indicates intent to fold Amplion capabilities into a broader life-sciences data and insights portfolio.